A set of guidelines (ICH Q1A-E, Q3A-B, Q5C, Q6A-B) has been made available by the World Health Organization (WHO) and the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) in order to help the European Union, Japan, and the United States accept stability data that is sufficient for registration by the regulatory authorities in these jurisdictions. Degradation of novel drug substances and drug products under conditions harsher than those under which they degrade more quickly is known as forced degradation. In addition to offering insight into the medication substance's degradation pathways and degradation products and aiding in the clarification of the degradation products' structural details, it is necessary to demonstrate the specificity of stability indicating methods. Studies on forced degradation provide insight into the molecule's chemical behavior, which aids in the creation of the formulation and packaging. Furthermore, the regulatory guidelines lack explanation on the performance of forced degradation experiments and are extremely generic in nature. As a result, this study addresses the current developments in forced degradation research by offering a plan for investigating degradation mechanisms and outlining analytical techniques useful in the creation of stability indicating methodologies.